SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schiffer, C. A. Articles by Papenberg, D. Search for Related Content PubMed PubMed Citation Articles by Schiffer, C. A. Articles by Papenberg, D. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients CA Schiffer, DE Hogge, J Aisner, JP Dutcher, EJ Lee and D Papenberg High-dose intravenous gammaglobulin (polyvalent immunoglobulin G) has been shown to be of benefit in some patients with immune thrombocytopenic purpura (ITP), possibly by producing reticuloendothelial system blockade. We studied this approach in patients refractory to random donor platelet transfusion using an IV IgG preparation manufactured by the Swiss Red Cross. Eleven adult patients with acute leukemia received either 0.4 g IgG/kg/d intravenously X five days (four patients) or 0.6 g/kg/d X five days (seven patients). All patients had high levels of lymphocytotoxic antibody and poor responses to random donor platelets. Except for mild headaches in two patients, there were no side effects related to the IgG infusions. All patients had significant elevations of serum IgG on the day after completion of treatment. Either random donor or partially HLA-matched platelet transfusions were administered the day after and, in some cases, during the IgG therapy. No patient had an improvement in one hour posttransfusion platelet count increments. Two additional patients received pooled platelet concentrates incubated for 30 minutes at 37 degrees C with IgG at a final concentration of 3 g% prior to transfusions. These results indicate that high-dose IgG, an extremely expensive treatment, cannot be recommended for alloimmunized adults with leukemia. Volume 64, Issue 4, pp. 937-940, 10/01/1984 Copyright © 1984 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. W. Semple, M. Kim, A. H. Lazarus, and J. Freedman gamma -Globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response Blood, July 18, 2002; 100(3): 1055 - 1059. [Abstract] [Full Text] [PDF] C. A. Schiffer, K. C. Anderson, C. L. Bennett, S. Bernstein, L. S. Elting, M. Goldsmith, M. Goldstein, H. Hume, J. J. McCullough, R. E. McIntyre, et al. Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1519 - 1538. [Abstract] [Full Text] [PDF] S. A. Berkman, M. L. Lee, and R. P. Gale Clinical Uses of Intravenous Immunoglobulins Ann Intern Med, February 15, 1990; 112(4): 278 - 292. [Abstract] [PDF]

	Copyright © 1984 by American Society of Hematology         Online ISSN: 1528-0020